Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Concerning Nivolumab & Esophageal Squamous Cell Carcinoma (ESCC), the phase III trial NCT02569242 showed, that Nivolumab was associated with a significant improvement in overall survival and a favourable safety profile compared with chemotherapy in previously treated patients with advanced Esophageal Squamous Cell Carcinoma (ESCC), and might represent a new standard second-line treatment option for these patients (1)
On June 10, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab for the treatment of patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinumbased chemotherapy (3).
Based on the…